An update on pharmacotherapy for the treatment of fibromyalgia

Bibliography

• Smith HS, Barkin RL. Fibromyalgia syndrome: a discussion of the syndrome and pharmacotherapy. Dis Mon 2011;57:248-85
   PubMed Web of Science ®Google Scholar
• Clauw DJ, Arnold LM, McCarberg BH. The science of fibromyalgia. Mayo Clin Proc 2011;86:907-11
   PubMed Web of Science ®Google Scholar
• Queiroz LP. Worldwide epidemiology of fibromyalgia. Curr Pain Headache Rep 2013;17:356
   PubMed Web of Science ®Google Scholar
• Weir PT, Harlan GA, Nkoy FL, et al. The incidence of fibromyalgia and its associated comorbidities: a population-based retrospective cohort study based on International Classification of Diseases, 9th Revision codes. J Clin Rheumatol 2006;12:124-8
   PubMed Web of Science ®Google Scholar
• Aaron LA, Buchwald D. Chronic diffuse musculoskeletal pain, fibromyalgia and co-morbid unexplained clinical conditions. Best Pract Res Clin Rheumatol 2003;17:563-74
   PubMed Web of Science ®Google Scholar
• White LA, Birnbaum HG, Kaltenboeck A, et al. Employees with fibromyalgia: medical comorbidity, healthcare costs, and work loss. J Occup Environ Med 2008;50:13-24
   PubMed Web of Science ®Google Scholar
• Skaer TL. Fibromyalgia: disease synopsis, medication cost effectiveness and economic burden. Pharmacoeconomics 2014;32:457-66
   PubMed Web of Science ®Google Scholar
• Sarzi-Puttini P, Atzeni F, Salaffi F, et al. Multidisciplinary approach to fibromyalgia: what is the teaching? Best Pract Res Clin Rheumatol 2011;25:311-19
   PubMed Web of Science ®Google Scholar
• Häuser W, Thieme K, Turk DC. Guidelines on the management of fibromyalgia syndrome - a systematic review. Eur J Pain 2010;14:5-10
   PubMed Web of Science ®Google Scholar
• Ablin J, Fitzcharles MA, Buskila D, et al. Treatment of fibromyalgia syndrome: recommendations of recent evidence-based interdisciplinary guidelines with special emphasis on complementary and alternative therapies. Evid Based Complement Alternat Med 2013;2013:485272
   PubMed Web of Science ®Google Scholar
• Carville SF, Arendt-Nielsen S, Bliddal H, et al. EULAR evidence-based recommendations for the management of fibromyalgia syndrome. Ann Rheum Dis 2008;67:536-41
   PubMed Web of Science ®Google Scholar
• Häuser W, Arnold B, Eich W, et al. Management of fibromyalgia syndrome--an interdisciplinary evidence-based guideline. Ger Med Sci 2008;6:Doc14
   PubMedGoogle Scholar
• de Miquel CA, Campayo J, Florez MT, et al. Interdisciplinary consensus document for the treatment of fibromyalgia. Actas Esp Psiquiatr 2010;38:108-20
   PubMed Web of Science ®Google Scholar
• Fitzcharles MA, Ste-Marie PA, Goldenberg DL, et al. 2012;Canadian Guidelines for the diagnosis and management of fibromyalgia syndrome: executive summary. Pain Res Manag 2013;18:119-26
   Google Scholar
• Mika J, Zychowska M, Makuch W, et al. Neuronal and immunological basis of action of antidepressants in chronic pain - clinical and experimental studies. Pharmacol Rep 2013;65:1611-21
   PubMed Web of Science ®Google Scholar
• Heymann RE, Helfenstein M, Feldman D. A double-blind, randomized, controlled study of amitriptyline, nortriptyline and placebo in patients with fibromyalgia. An analysis of outcome measures. Clin Exp Rheumatol 2001;19:697-702
   PubMed Web of Science ®Google Scholar
• Caruso I, Sarzi Puttini PC, Boccassini L, et al. Double-blind study of dothiepin versus placebo in the treatment of primary fibromyalgia syndrome. J Int Med Res 1987;15:154-9
   PubMed Web of Science ®Google Scholar
• Carette S, McCain GA, Bell DA, et al. Evaluation of amitriptyline in primary fibrositis. A double-blind, placebo-controlled study. Arthritis Rheum 1986;29:655-9
   PubMed Web of Science ®Google Scholar
• Carette S, Bell MJ, Reynolds WJ, et al. Comparison of amitriptyline, cyclobenzaprine, and placebo in the treatment of fibromyalgia. A randomized, double-blind clinical trial. Arthritis Rheum 1994;37:32-40
   PubMed Web of Science ®Google Scholar
• Carette S, Oakson G, Guimont C, et al. Sleep electroencephalography and the clinical response to amitriptyline in patients with fibromyalgia. Arthritis Rheum 1995;38:1211-17
   PubMed Web of Science ®Google Scholar
• Goldenberg DL, Felson DT, Dinerman H. A randomized, controlled trial of amitriptyline and naproxen in the treatment of patients with fibromyalgia. Arthritis Rheum 1986;29:1371-7
   PubMed Web of Science ®Google Scholar
• Goldenberg D, Mayskiy M, Mossey C, et al. A randomized, double-blind crossover trial of fluoxetine and amitriptyline in the treatment of fibromyalgia. Arthritis Rheum 1996;39:1852-9
   PubMed Web of Science ®Google Scholar
• Scudds RA, McCain GA, Rollman GB, et al. Improvements in pain responsiveness in patients with fibrositis after successful treatment with amitriptyline. J Rheumatol Suppl 1989;19:98-103
   PubMedGoogle Scholar
• Isomeri R, Mikkelsson M, Latikka P, et al. Effects of amitriptyline and cardiovascular fitness training on pain in patients with primary fibromyalgia. J Musculoskelet Pain 1993;1:253-60
   Google Scholar
• Kempenaers C, Simenon G, Vander Elst M, et al. Effect of an antidiencephalon immune serum on pain and sleep in primary fibromyalgia. Neuropsychobiology 1994;30:66-72
   PubMed Web of Science ®Google Scholar
• Ginsberg F, Mancaux A, Joos E, et al. A randomized placebo-controlled trial of sustained-release amitriptyline in primary fibromyalgia. J Musculoskelet Pain 1996;4:37-47
   Google Scholar
• Ataoglu S, Ataoglu A, Erdogan F, et al. Comparison of paroxetine, amitriptyline in the treatment of fibromyalgia. Turk J Med Sci 1997;27:535-9
   Google Scholar
• Hannonen P, Malminiemi K, Yli-Kerttula U, et al. A randomized, double-blind, placebo-controlled study of moclobemide and amitriptyline in the treatment of fibromyalgia in females without psychiatric disorder. Br J Rheumatol 1998;37:1279-86
   PubMedGoogle Scholar
• Çapaci K, Hepgüler S. Comparison of the effects of amitriptyline and paroxetine in the treatment of fibromyalgia syndrome. Pain Clinic 2002;14:223-8
   Web of Science ®Google Scholar
• Gur A, Karakoc M, Nas K, et al. Effects of low power laser and low dose amitriptyline therapy on clinical symptoms and quality of life in fibromyalgia: a single-blind, placebo-controlled trial. Rheumatol Int 2002;22:188-93
   PubMed Web of Science ®Google Scholar
• Konuk N, Ortancil O, Bostanci B, et al. A comparison of reboxetine and amitryptilline in the treatment of fibromyalgia syndrome with co-morbid depressive symptoms: An open-label preliminary study. Klin Psikofarmakol Bul 2010;20:29-37
   Web of Science ®Google Scholar
• Vlainich R, Issy AM, Sakata RK. Effect of intravenous lidocaine associated with amitriptyline on pain relief and plasma serotonin, norepinephrine, and dopamine concentrations in fibromyalgia. Clin J Pain 2011;27:285-8
   PubMed Web of Science ®Google Scholar
• Calandre EP, Rico-Villademoros F, Galan J, et al. Quetiapine extended-release (Seroquel-XR) versus amitriptyline monotherapy for treating patients with fibromyalgia: a 16-week, randomized, flexible-dose, open-label trial. Psychopharmacology (Berl) 2014;231:2525-31
   PubMed Web of Science ®Google Scholar
• Erhan E, Uyar M, Turan S, et al. Fluvoxamine versus amitriptyline in the treatment of fibromyalgia. Agri 2000;12:32-6
   Google Scholar
• Häuser W, Petzke F, Uceyler N, et al. Comparative efficacy and acceptability of amitriptyline, duloxetine and milnacipran in fibromyalgia syndrome: a systematic review with meta-analysis. Rheumatology (Oxford) 2011;50:532-43
   PubMed Web of Science ®Google Scholar
• Smith B, Peterson K, Fu R, et al. Drug Class Review: Drugs for Fibromyalgia: Final Original Report [Internet]. 2011/06/21 edition. Oregon Health & Science University; Portland (OR): 2011
   Google Scholar
• Arnold LM, Lu Y, Crofford LJ, et al. A double-blind, multicenter trial comparing duloxetine with placebo in the treatment of fibromyalgia patients with or without major depressive disorder. Arthritis Rheum 2004;50:2974-84
   PubMed Web of Science ®Google Scholar
• Arnold LM, Rosen A, Pritchett YL, et al. A randomized, double-blind, placebo-controlled trial of duloxetine in the treatment of women with fibromyalgia with or without major depressive disorder. Pain 2005;119:5-15
   PubMed Web of Science ®Google Scholar
• Arnold LM, Clauw D, Wang F, et al. Flexible dosed duloxetine in the treatment of fibromyalgia: a randomized, double-blind, placebo-controlled trial. J Rheumatol 2010;37:2578-86
   PubMed Web of Science ®Google Scholar
• Arnold LM, Wang F, Ahl J, et al. Improvement in multiple dimensions of fatigue in patients with fibromyalgia treated with duloxetine: secondary analysis of a randomized, placebo-controlled trial. Arthritis Res Ther 2011;13:R86
   PubMed Web of Science ®Google Scholar
• Arnold LM, Zhang S, Pangallo BA. Efficacy and safety of duloxetine 30 mg/d in patients with fibromyalgia: a randomized, double-blind, placebo-controlled study. Clin J Pain 2012;28:775-81
   PubMed Web of Science ®Google Scholar
• Russell IJ, Mease PJ, Smith TR, et al. Efficacy and safety of duloxetine for treatment of fibromyalgia in patients with or without major depressive disorder: Results from a 6-month, randomized, double-blind, placebo-controlled, fixed-dose trial. Pain 2008;136:432-44
   PubMed Web of Science ®Google Scholar
• Chappell AS, Bradley LA, Wiltse C, et al. A six-month double-blind, placebo-controlled, randomized clinical trial of duloxetine for the treatment of fibromyalgia. Int J Gen Med 2008;1:91-102
   PubMedGoogle Scholar
• Chappell AS, Littlejohn G, Kajdasz DK, et al. A 1-year safety and efficacy study of duloxetine in patients with fibromyalgia. Clin J Pain 2009;25:365-75
   PubMed Web of Science ®Google Scholar
• Gendreau RM, Thorn MD, Gendreau JF, et al. Efficacy of milnacipran in patients with fibromyalgia. J Rheumatol 2005;32:1975-85
   PubMed Web of Science ®Google Scholar
• Clauw DJ, Mease P, Palmer RH, et al. Milnacipran for the treatment of fibromyalgia in adults: a 15-week, multicenter, randomized, double-blind, placebo-controlled, multiple-dose clinical trial. Clin Ther 2008;30:1988-2004
   PubMed Web of Science ®Google Scholar
• Mease PJ, Clauw DJ, Gendreau RM, et al. The efficacy and safety of milnacipran for treatment of fibromyalgia. a randomized, double-blind, placebo-controlled trial. J Rheumatol 2009;36:398-409
   PubMed Web of Science ®Google Scholar
• Arnold LM, Gendreau RM, Palmer RH, et al. Efficacy and safety of milnacipran 100 mg/day in patients with fibromyalgia: results of a randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2010;62:2745-56
   PubMed Web of Science ®Google Scholar
• Arnold LM, Palmer RH, Ma Y. A. 3-year, open-label, flexible-dosing study of milnacipran for the treatment of fibromyalgia. Clin J Pain 2013;29:1021-8
   PubMedGoogle Scholar
• Goldenberg DL, Clauw DJ, Palmer RH, et al. Durability of therapeutic response to milnacipran treatment for fibromyalgia. Results of a randomized, double-blind, monotherapy 6-month extension study. Pain Med 2010;11:180-94
   PubMed Web of Science ®Google Scholar
• Branco JC, Zachrisson O, Perrot S, et al. A European multicenter randomized double-blind placebo-controlled monotherapy clinical trial of milnacipran in treatment of fibromyalgia. J Rheumatol 2010;37:851-9
   PubMed Web of Science ®Google Scholar
• Branco JC, Cherin P, Montagne A, et al. Longterm therapeutic response to milnacipran treatment for fibromyalgia. A European 1-year extension study following a 3-month study. J Rheumatol 2011;38:1403-12
   PubMed Web of Science ®Google Scholar
• Matthey A, Cedraschi C, Piguet V, et al. Dual reuptake inhibitor milnacipran and spinal pain pathways in fibromyalgia patients: a randomized, double-blind, placebo-controlled trial. Pain Physician 2013;16:E553-62
   Google Scholar
• Bateman L, Palmer RH, Trugman JM, et al. Results of switching to milnacipran in fibromyalgia patients with an inadequate response to duloxetine: a phase IV pilot study. J Pain Res 2013;6:311-18
   PubMed Web of Science ®Google Scholar
• Häuser W, Urrutia G, Tort S, et al. Serotonin and noradrenaline reuptake inhibitors (SNRIs) for fibromyalgia syndrome. The Cochrane database of systematic reviews 2013;1:CD010292
   PubMedGoogle Scholar
• Norregaard J, Volkmann H, Danneskiold-Samsoe B. A randomized controlled trial of citalopram in the treatment of fibromyalgia. Pain 1995;61:445-9
   PubMed Web of Science ®Google Scholar
• Anderberg UM, Marteinsdottir I, von Knorring L. Citalopram in patients with fibromyalgia--a randomized, double-blind, placebo-controlled study. Eur J Pain 2000;4:27-35
   PubMed Web of Science ®Google Scholar
• Kayiran S, Dursun E, Dursun N, et al. Neurofeedback intervention in fibromyalgia syndrome; a randomized, controlled, rater blind clinical trial. Appl Psychophysiol Biofeedback 2010;35:293-302
   PubMed Web of Science ®Google Scholar
• Wolfe F, Cathey MA, Hawley DJ. A double-blind placebo controlled trial of fluoxetine in fibromyalgia. Scand J Rheumatol 1994;23:255-9
   PubMed Web of Science ®Google Scholar
• Cantini F, Bellandi F, Niccoli L, et al. [Fluoxetin combined with cyclobenzaprine in the treatment of fibromyalgia]. Minerva Med 1994;85:97-100
   PubMedGoogle Scholar
• Cantini F, Niccoli L, Bellandi F, et al. Effectiveness of fluoxetine associated with cyclobenzaprine in the treatment of fibromyalgia: Twelve-months-follow up results. Reumatismo 1995;47:103-8
   Google Scholar
• Arnold LM, Hess EV, Hudson JI, et al. A randomized, placebo-controlled, double-blind, flexible-dose study of fluoxetine in the treatment of women with fibromyalgia. Am J Med 2002;112:191-7
   PubMed Web of Science ®Google Scholar
• Hadianfard MJ, Hosseinzadeh Parizi M. A randomized clinical trial of fibromyalgia treatment with acupuncture compared with fluoxetine. Iran Red Crescent Med J 2012;14:631-40
   PubMed Web of Science ®Google Scholar
• Giordano N, Geraci S, Santacroce C, et al. Efficacy and tolerability of paroxetine in patients with fibromyalgia syndrome: A single-blind study. Curr Ther Res Clin Exp 1999;60:696-702
   Web of Science ®Google Scholar
• Sencan S, Ak S, Karan A, et al. A study to compare the therapeutic efficacy of aerobic exercise and paroxetine in fibromyalgia syndrome. J Back Musculoskelet Rehabil 2004;17:57-61
   Web of Science ®Google Scholar
• Patkar AA, Masand PS, Krulewicz S, et al. A Randomized, Controlled, Trial of Controlled Release Paroxetine in Fibromyalgia. Am J Med 2007;120:448-54
   PubMed Web of Science ®Google Scholar
• González-Viejo MA, Avellanet M, Hernández-Morcuende MI. A comparative study of fibromyalgia treatment: Ultrasonography and physiotherapy versus sertraline treatment. Ann Readapt Med Phys 2005;48:610-15
   PubMedGoogle Scholar
• Häuser W, Wolfe F, Tolle T, et al. The role of antidepressants in the management of fibromyalgia syndrome: a systematic review and meta-analysis. CNS Drugs 2012;26:297-307
   PubMed Web of Science ®Google Scholar
• Yavuzer G, Kucukdeveci A, Arasil T, et al. Moclobemid treatment in primary fibromyalgia syndrome. Eur J Phys Med Rehabil 1998;8:35-8
   Google Scholar
• Ginsberg F, Joos E, Géczy J, et al. A pilot randomized placebo-controlled study of pirlindole in the treatment of primary fibromyalgia. J Musculoskelet Pain 1998;6:5-17
   Web of Science ®Google Scholar
• Crofford LJ, Rowbotham MC, Mease PJ, et al. Pregabalin for the treatment of fibromyalgia syndrome: results of a randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2005;52:1264-73
   PubMed Web of Science ®Google Scholar
• Crofford LJ, Mease PJ, Simpson SL, et al. Fibromyalgia relapse evaluation and efficacy for durability of meaningful relief (FREEDOM): a 6-month, double-blind, placebo-controlled trial with pregabalin. Pain 2008;136:419-31
   PubMed Web of Science ®Google Scholar
• Mease PJ, Russell IJ, Arnold LM, et al. A randomized, double-blind, placebo-controlled, phase III trial of pregabalin in the treatment of patients with fibromyalgia. J Rheumatol 2008;35:502-14
   PubMed Web of Science ®Google Scholar
• Mease PJ, Farmer MV, Palmer RH, et al. Milnacipran combined with pregabalin in fibromyalgia: a randomized, open-label study evaluating the safety and efficacy of adding milnacipran in patients with incomplete response to pregabalin. Ther Adv Musculoskelet Dis 2013;5:113-26
   PubMedGoogle Scholar
• Arnold LM, Goldenberg DL, Stanford SB, et al. Gabapentin in the treatment of fibromyalgia: a randomized, double-blind, placebo-controlled, multicenter trial. Arthritis Rheum 2007;56:1336-44
   PubMed Web of Science ®Google Scholar
• Arnold LM, Russell IJ, Diri EW, et al. A 14-week, randomized, double-blinded, placebo-controlled monotherapy trial of pregabalin in patients with fibromyalgia. J Pain 2008;9:792-805
   PubMed Web of Science ®Google Scholar
• Pauer L, Winkelmann A, Arsenault P, et al. An international, randomized, double-blind, placebo-controlled, phase III trial of pregabalin monotherapy in treatment of patients with fibromyalgia. J Rheumatol 2011;38:2643-52
   PubMed Web of Science ®Google Scholar
• Roth T, Lankford DA, Bhadra P, et al. Effect of pregabalin on sleep in patients with fibromyalgia and sleep maintenance disturbance: a randomized, placebo-controlled, 2-way crossover polysomnography study. Arthritis Care Res (Hoboken) 2012;64:597-606
   PubMed Web of Science ®Google Scholar
• Ohta H, Oka H, Usui C, et al. A randomized, double-blind, multicenter, placebo-controlled phase III trial to evaluate the efficacy and safety of pregabalin in Japanese patients with fibromyalgia. Arthritis Res Ther 2012;14:R217
   PubMed Web of Science ®Google Scholar
• Ohta H, Oka H, Usui C, et al. An open-label long-term phase III extension trial to evaluate the safety and efficacy of pregabalin in Japanese patients with fibromyalgia. Mod Rheumatol 2013;23:1108-15
   PubMed Web of Science ®Google Scholar
• Nasser K, Kivitz AJ, Maricic MJ, et al. Twice daily versus once nightly dosing of pregabalin for fibromyalgia: a double-blind randomized clinical trial of efficacy and safety. Arthritis Care Res (Hoboken) 2014;66:293-300
   PubMed Web of Science ®Google Scholar
• Häuser W, Bernardy K, Uceyler N, et al. Treatment of fibromyalgia syndrome with gabapentin and pregabalin--a meta-analysis of randomized controlled trials. Pain 2009;145:69-81
   PubMed Web of Science ®Google Scholar
• Bennett RM, Gatter RA, Campbell SM, et al. A comparison of cyclobenzaprine and placebo in the management of fibrositis. A double-blind controlled study. Arthritis Rheum 1988;31:1535-42
   PubMed Web of Science ®Google Scholar
• Quimby LG, Gratwick GM, Whitney CD, et al. A randomized trial of cyclobenzaprine for the treatment of fibromyalgia. J Rheumatol Suppl 1989;19:140-3
   PubMedGoogle Scholar
• Reynolds WJ, Moldofsky H, Saskin P, et al. The effects of cyclobenzaprine on sleep physiology and symptoms in patients with fibromyalgia. J Rheumatol 1991;18:452-4
   PubMed Web of Science ®Google Scholar
• Fossaluzza V, De Vita S. Combined therapy with cyclobenzaprine and ibuprofen in primary fibromyalgia syndrome. Int J Clin Pharmacol Res 1992;12:99-102
   PubMedGoogle Scholar
• Santandrea S, Montrone F, Sarzi-Puttini P, et al. A double-blind crossover study of two cyclobenzaprine regimens in primary fibromyalgia syndrome. J Int Med Res 1993;21:74-80
   PubMed Web of Science ®Google Scholar
• Garcia J, Simon MA, Duran M, et al. Differential efficacy of a cognitive-behavioral intervention versus pharmacological treatment in the management of fibromyalgic syndrome. Psychol Health Med 2006;11:498-506
   PubMedGoogle Scholar
• Moldofsky H, Harris HW, Archambault WT, et al. Effects of bedtime very low dose cyclobenzaprine on symptoms and sleep physiology in patients with fibromyalgia syndrome: a double-blind randomized placebo-controlled study. J Rheumatol 2011;38:2653-63
   PubMed Web of Science ®Google Scholar
• Tofferi JK, Jackson JL, O’Malley PG. Treatment of fibromyalgia with cyclobenzaprine: A meta-analysis. Arthritis Rheum 2004;51:9-13
   PubMed Web of Science ®Google Scholar
• Biasi G, Manca S, Manganelli S, et al. Tramadol in the fibromyalgia syndrome: a controlled clinical trial versus placebo. Int J Clin Pharmacol Res 1998;18:13-19
   PubMedGoogle Scholar
• Russell IJ, Kamin M, Bennett RM, et al. Efficacy of tramadol in treatment of pain in fibromyalgia. J Clin Rheumatol 2000;6:250-7
   PubMed Web of Science ®Google Scholar
• Bennett RM, Kamin M, Karim R, et al. Tramadol and acetaminophen combination tablets in the treatment of fibromyalgia pain: a double-blind, randomized, placebo-controlled study. Am J Med 2003;114:537-45
   PubMed Web of Science ®Google Scholar
• Farber L, Stratz T, Bruckle W, et al. Efficacy and tolerability of tropisetron in primary fibromyalgia--a highly selective and competitive 5-HT3 receptor antagonist. German Fibromyalgia Study Group. Scand J Rheumatol Suppl 2000;113:49-54
   PubMedGoogle Scholar
• Spath M, Stratz T, Neeck G, et al. Efficacy and tolerability of intravenous tropisetron in the treatment of fibromyalgia. Scand J Rheumatol 2004;33:267-70
   PubMed Web of Science ®Google Scholar
• Seidel MF, Weinreich GF, Stratz T, et al. 5-HT3 receptor antagonists regulate autonomic cardiac dysfunction in primary fibromyalgia syndrome. Rheumatol Int 2007;27:1025-30
   PubMed Web of Science ®Google Scholar
• Vergne-Salle P, Dufauret-Lombard C, Bonnet C, et al. A randomised, double-blind, placebo-controlled trial of dolasetron, a 5-hydroxytryptamine 3 receptor antagonist, in patients with fibromyalgia. Eur J Pain 2011;15:509-14
   PubMed Web of Science ®Google Scholar
• Holman AJ, Myers RR. A randomized, double-blind, placebo-controlled trial of pramipexole, a dopamine agonist, in patients with fibromyalgia receiving concomitant medications. Arthritis Rheum 2005;52:2495-505
   PubMed Web of Science ®Google Scholar
• Wood PB, Holman AJ. An elephant among us: the role of dopamine in the pathophysiology of fibromyalgia. J Rheumatol 2009;36:221-4
   PubMed Web of Science ®Google Scholar
• Staud R. Sodium oxybate for the treatment of fibromyalgia. Expert Opin Pharmacother 2011;12:1789-98
   PubMed Web of Science ®Google Scholar
• Scharf MB, Baumann M, Berkowitz DV. The effects of sodium oxybate on clinical symptoms and sleep patterns in patients with fibromyalgia. J Rheumatol 2003;30:1070-4
   PubMed Web of Science ®Google Scholar
• Russell IJ, Perkins AT, Michalek JE. Sodium oxybate relieves pain and improves function in fibromyalgia syndrome: a randomized, double-blind, placebo-controlled, multicenter clinical trial. Arthritis Rheum 2009;60:299-309
   PubMed Web of Science ®Google Scholar
• Russell IJ, Holman AJ, Swick TJ, et al. Sodium oxybate reduces pain, fatigue, and sleep disturbance and improves functionality in fibromyalgia: results from a 14-week, randomized, double-blind, placebo-controlled study. Pain 2011;152:1007-17
   PubMed Web of Science ®Google Scholar
• Spaeth M, Bennett RM, Benson BA, et al. Sodium oxybate therapy provides multidimensional improvement in fibromyalgia: results of an international phase 3 trial. Ann Rheum Dis 2012;71:935-42
   PubMed Web of Science ®Google Scholar
• Spaeth M, Alegre C, Perrot S, et al. Long-term tolerability and maintenance of therapeutic response to sodium oxybate in an open-label extension study in patients with fibromyalgia. Arthritis Res Ther 2013;15:R185
   Google Scholar
• Skrabek RQ, Galimova L, Ethans K, et al. Nabilone for the treatment of pain in fibromyalgia. J Pain 2008;9:164-73
   PubMed Web of Science ®Google Scholar
• Ware MA, Fitzcharles MA, Joseph L, et al. The effects of nabilone on sleep in fibromyalgia: results of a randomized controlled trial. Anesth Analg 2010;110:604-10
   PubMed Web of Science ®Google Scholar
• Arnold LM, Chatamra K, Hirsch I, et al. Safety and efficacy of esreboxetine in patients with fibromyalgia: An 8-week, multicenter, randomized, double-blind, placebo-controlled study. Clin Ther 2010;32:1618-32
   PubMed Web of Science ®Google Scholar
• Arnold LM, Hirsch I, Sanders P, et al. Safety and efficacy of esreboxetine in patients with fibromyalgia: a fourteen-week, randomized, double-blind, placebo-controlled, multicenter clinical trial. Arthritis Rheum 2012;64:2387-97
   PubMed Web of Science ®Google Scholar
• Yeephu S, Suthisisang C, Suttiruksa S, et al. Efficacy and safety of mirtazapine in fibromyalgia syndrome patients: a randomized placebo-controlled pilot study. Ann Pharmacother 2013;47:921-32
   PubMed Web of Science ®Google Scholar
• Hussain SA, Al KII, Jasim NA, et al. Adjuvant use of melatonin for treatment of fibromyalgia. J Pineal Res 2011;50:267-71
   PubMed Web of Science ®Google Scholar
• de Zanette SA, Vercelino R, Laste G, et al. Melatonin analgesia is associated with improvement of the descending endogenous pain-modulating system in fibromyalgia: a phase II, randomized, double-dummy, controlled trial. BMC Pharmacol Toxicol 2014;15:40
   PubMed Web of Science ®Google Scholar
• Rico-Villademoros F, Calandre EP, Slim M. Current Status of Atypical Antipsychotics for the Treatment of Fibromyalgia. Drug Today 2014;50:435-44
   PubMed Web of Science ®Google Scholar
• Olivan-Blazquez B, Herrera-Mercadal P, Puebla-Guedea M, et al. Efficacy of memantine in the treatment of fibromyalgia: A double-blind, randomised, controlled trial with 6-month follow-up. Pain 2014;155:2517-25
   PubMed Web of Science ®Google Scholar
• Boyle J, Eriksson ME, Gribble L, et al. Randomized, placebo-controlled comparison of amitriptyline, duloxetine, and pregabalin in patients with chronic diabetic peripheral neuropathic pain: impact on pain, polysomnographic sleep, daytime functioning, and quality of life. Diabetes Care 2012;35:2451-8
   PubMed Web of Science ®Google Scholar
• Clauw DJ. Fibromyalgia: a clinical review. JAMA 2014;311:1547-55
   PubMed Web of Science ®Google Scholar
• Wolfe F, Hawley DJ, Wilson K. The prevalence and meaning of fatigue in rheumatic disease. J Rheumatol 1996;23:1407-17
   PubMed Web of Science ®Google Scholar
• Moldofsky H, Inhaber NH, Guinta DR, et al. Effects of sodium oxybate on sleep physiology and sleep/wake-related symptoms in patients with fibromyalgia syndrome: a double-blind, randomized, placebo-controlled study. J Rheumatol 2010;37:2156-66
   PubMed Web of Science ®Google Scholar
• Holshoe JM. Antidepressants and sleep: a review. Perspect Psychiatr Care 2009;45:191-7
   PubMedGoogle Scholar
• Stahl SM. The psychopharmacology of energy and fatigue. J Clin Psychiatry 2002;63:7-8
   PubMed Web of Science ®Google Scholar
• Mease PJ, Palmer RH, Wang Y. Effects of milnacipran on the multidimensional aspects of fatigue and the relationship of fatigue to pain and function: pooled analysis of 3 fibromyalgia trials. J Clin Rheumatol 2014;20:195-202
   PubMedGoogle Scholar
• Wolfe F, Anderson J, Harkness D, et al. A prospective, longitudinal, multicenter study of service utilization and costs in fibromyalgia. Arthritis Rheum 1997;40:1560-70
   PubMed Web of Science ®Google Scholar
• White KP, Nielson WR, Harth M, et al. Does the label “fibromyalgia” alter health status, function, and health service utilization? A prospective, within-group comparison in a community cohort of adults with chronic widespread pain. Arthritis Rheum 2002;47:260-5
   PubMed Web of Science ®Google Scholar
• Wolfe F, Smythe HA, Yunus MB, et al. The American College of Rheumatology 1990 Criteria for the Classification of Fibromyalgia. Report of the Multicenter Criteria Committee. Arthritis Rheum 1990;33:160-72
   PubMed Web of Science ®Google Scholar
• Calandre EP, Rico-Villademoros F, Rodriguez-Lopez CM. Monotherapy or combination therapy for fibromyalgia treatment? Curr Rheumatol Rep 2012;14:568-75
   PubMed Web of Science ®Google Scholar